Ehab L. Atallah, MD

Publications

• Real-World Evaluation of Treatment Patterns and Clinical Outcomes among Patients With Chronic Myeloid Leukemia in Chronic Phase Treated With Asciminib in Clinical Practice in the United States: Real-world asciminib treatment outcomes in CML-CP.

  (Atallah EL, Wei D, Latremouille-Viau D, Rossi C, Damon A, Ferreira G, Guérin A, Jadhav K.) Clin Lymphoma Myeloma Leuk. 2025 Mar;25(3):178-187.e2 PMID: 39426944 SCOPUS ID: 2-s2.0-85206926730 10/20/2024

• Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia.

  (Abedin SM, Guru Murthy GS, Hamadani M, Michaelis LC, Carlson KS, Runaas L, Gauger K, Desai AG, Chen MM, Li KL, Rotibi M, Syed U, Vusirikala M, Harrington A, Atallah EL.) Leukemia. 2025 Feb 15 PMID: 39955432 SCOPUS ID: 2-s2.0-85218187693 02/16/2025

• 40 is the new 50: reducing the need for platelet transfusions prior to lumbar puncture in adults with hematologic malignancies.

  (Corrao K, Umpierrez A, Treml A, Szabo A, Michaelis L, Runaas L, Murthy GSG, Abedin S, Carlson K, Kreuziger LB, Atallah E.) Haematologica. 2025 Jan 30 PMID: 39882645 01/30/2025

• Advanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations.

  (Atallah E, Deininger M.) Drugs. 2025 Jan;85(1):41-50 PMID: 39638957 SCOPUS ID: 2-s2.0-85216136135 12/06/2024

• Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A multi-institutional study.

  (Badar T, Narra R, Mims AS, Heckman MG, Shallis RM, Fahad S, Hunter C, Kota V, Othman TA, Jonas B, Desai S, de Camargo Correia GS, Patel A, DuVall AS, Palmisiano N, Curran E, Omer Z, Advani A, Atallah E, Litzow M.) Am J Hematol. 2024 Dec;99(12):2388-2391 PMID: 39253997 SCOPUS ID: 2-s2.0-85203436363 09/10/2024

• Prognostic impact of 'multi-hit' <i>versus</i> 'single-hit' <i>TP53</i> alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases.

  (Badar T, Nanaa A, Atallah E, Shallis RM, Craver EC, Li Z, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, Duvall A, Burkart M, Bradshaw D, Abaza Y, Stahl M, Palmisiano N, Murthy GSG, Zeidan AM, Kota V, Patnaik MM, Litzow MR.) Haematologica. 2024 Nov 01;109(11):3533-3542 PMID: 38813716 PMCID: PMC11532685 SCOPUS ID: 2-s2.0-85206113727 05/30/2024

• A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B-cell or T-cell acute lymphoblastic leukemia: Results from the ECOG-ACRIN EA9152 protocol.

  (Palmisiano ND, Lee JW, Claxton DF, Paietta EM, Alkhateeb H, Park J, Podoltsev NA, Atallah EL, Schaar DG, Dinner SN, Webster JA, Luger SM, Litzow MR.) EJHaem. 2024 Oct;5(5):951-956 PMID: 39415930 PMCID: PMC11474352 10/17/2024

• Transplant or no transplant for TP53 mutated AML.

  (Badar T, Shahzad M, Atallah E, Litzow MR, Kharfan-Dabaja MA.) Oncotarget. 2024 Oct 01;15:674-676 PMID: 39352794 PMCID: PMC11444334 SCOPUS ID: 2-s2.0-85205527584 10/03/2024

• BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysis.

  (Kockerols C, Valk PJM, Dulucq S, Nicolini FE, Mahon FX, Atallah E, Mauro MJ, Radich JP, Bernardi S, Russo D, Farina M, Mori S, Gambacorti-Passerini C, Civettini I, Lu L, Yeung D, Branford S, Colafigli G, Breccia M, Hogenbirk P, van Rosmalen J, Cornelissen JJ, Westerweel PE.) Am J Hematol. 2024 Aug;99(8):1632-1635 PMID: 38769689 SCOPUS ID: 2-s2.0-85193735288 05/21/2024

• Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.

  (Litzow MR, Sun Z, Mattison RJ, Paietta EM, Roberts KG, Zhang Y, Racevskis J, Lazarus HM, Rowe JM, Arber DA, Wieduwilt MJ, Liedtke M, Bergeron J, Wood BL, Zhao Y, Wu G, Chang TC, Zhang W, Pratz KW, Dinner SN, Frey N, Gore SD, Bhatnagar B, Atallah EL, Uy GL, Jeyakumar D, Lin TL, Willman CL, DeAngelo DJ, Patel SB, Elliott MA, Advani AS, Tzachanis D, Vachhani P, Bhave RR, Sharon E, Little RF, Erba HP, Stone RM, Luger SM, Mullighan CG, Tallman MS.) N Engl J Med. 2024 Jul 25;391(4):320-333 PMID: 39047240 PMCID: PMC11334054 SCOPUS ID: 2-s2.0-85199977304 07/26/2024

• Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

  (Badar T, Nanaa A, Atallah E, Shallis RM, Guilherme SdCC, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, DuVall AS, Bradshaw D, Abaza Y, Murthy GSG, Palmisiano N, Zeidan AM, Kota V, Litzow MR.) Blood Cancer Journal. December 2024;14(1) SCOPUS ID: 2-s2.0-85185454442 12/01/2024

• Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial.

  (Atallah EL, Mauro MJ, Sasaki K, Levy MY, Koller P, Yang D, Laine D, Sabo J, Gu E, Cortes JE.) Future Oncol. 2024;20(38):3065-3075 PMID: 39387441 SCOPUS ID: 2-s2.0-85206143267 10/13/2024